Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxinium in Advanced SCCHN
NCT00412776Phase 3Terminated
- Sponsor
- Sesen Bio
- Start
- Dec 2005
- Primary completion
- Apr 2008
- Modality
- scFv Fragments, Antibody-Drug Conjugates (ADCs), Immunotoxins
- Countries
- 18
01
Overview
A Phase 3 trial of oportuzumab monatox in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Sesen Bio. Started Dec 2005; status: terminated.
02
Drugs
oportuzumab monatox
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00412776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412776.